211 related articles for article (PubMed ID: 30137199)
21. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.
Jiang YQ; Zhang Z; Cai HR; Zhou H
Int J Clin Exp Pathol; 2015; 8(11):13785-94. PubMed ID: 26823692
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.
Galal El-Shemi A; Mohammed Ashshi A; Oh E; Jung BK; Basalamah M; Alsaegh A; Yun CO
Gene Ther; 2018 Jan; 25(1):54-65. PubMed ID: 28925992
[TBL] [Abstract][Full Text] [Related]
23. Conditionally replicating oncolytic adenoviral vector expressing arresten and tumor necrosis factor-related apoptosis-inducing ligand experimentally suppresses lung carcinoma progression.
Li S; Qi Z; Li H; Hu J; Wang D; Wang X; Feng Z
Mol Med Rep; 2015 Aug; 12(2):2068-74. PubMed ID: 25891208
[TBL] [Abstract][Full Text] [Related]
24. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models.
Chaurasiya S; Chen NG; Lu J; Martin N; Shen Y; Kim SI; Warner SG; Woo Y; Fong Y
Cancer Gene Ther; 2020 Apr; 27(3-4):125-135. PubMed ID: 31209267
[TBL] [Abstract][Full Text] [Related]
25. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia.
Wang Z; Liu W; Wang L; Gao P; Li Z; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
Signal Transduct Target Ther; 2020 Apr; 5(1):40. PubMed ID: 32327638
[TBL] [Abstract][Full Text] [Related]
26. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
27. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
[TBL] [Abstract][Full Text] [Related]
28. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.
Sathaiah M; Thirunavukkarasu P; O'Malley ME; Kavanagh MA; Ravindranathan R; Austin F; Guo ZS; Bartlett DL
Cancer Gene Ther; 2012 Mar; 19(3):192-201. PubMed ID: 22116377
[TBL] [Abstract][Full Text] [Related]
31. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
33. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
[TBL] [Abstract][Full Text] [Related]
34. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.
Yang Y; Xu H; Shen J; Yang Y; Wu S; Xiao J; Xu Y; Liu XY; Chu L
Cell Death Dis; 2015 May; 6(5):e1760. PubMed ID: 25973680
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis.
Lv C; Su Q; Liang Y; Hu J; Yuan S
Biochem Biophys Res Commun; 2016 Jul; 476(1):21-8. PubMed ID: 27208781
[TBL] [Abstract][Full Text] [Related]
37. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
[TBL] [Abstract][Full Text] [Related]
38. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
39. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
40. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]